<?xml version="1.0" encoding="UTF-8"?>
<p id="para370">The proportions of CHOP and GEM-P treatments requiring G-CSF support were 135 (62%) of 219 and 70 (54%) of 130, respectively. Two patients (5%) of 43 in the CHOP group and four (9%) of 44 in the GEM-P group received prophylaxis for CNS relapse during the study: four (9%) received intrathecal methotrexate, one (2%) received intrathecal methotrexate plus methotrexate, cytarabine, and hydrocortisone, and one (2%) received unspecified therapy.</p>
